1Cannistra S. Is there a best choice of the second - line agent in the treatment of recurrent potentially platinum - sensitive ovarian canc- er[ J ]. J C lin 0ncol,2002,20 (5) : 1158 - 1160.
2Rowinsy EK, Grochow LB, Hendricks CB, et al. Phase I and phar- macological study of topotecan : a new novel topoisomerase I inhib- itor [ J]. J Clin Onco1,1992,10(4) :647-656.
3Mcguire WP, Blessing JA, Bookman MA, et al. Topotecan has sub- stantial antitumor activity as first - line salvage therapy in platinum -sensitive epithelial ovarian carcinoma : a gynecologic oncologygroup study[ J]. J Clin Onco1,2000,18 ( 5 ) : 1062 - 1067.
4Gore M ,Ten Bokkel, Huinink W, et al. Clinical evidence for topote- can - paclitaxel non - cross - resistance in ovarian cancer [ J ]. J Clin Oncol,2001,19 (7) :1893 - 1900.
5Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treat- ment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisp latin or carbop latin and paclitaxel [ J]. J Clin Oncol, 1998, 16:3345 - 3352.
2Friebe Z, Watrowski R, Bembnista M , et al. Correlation between p-latelet count and CA - 125 in ovarian cancer [ J ]. Ginekol Pol,2005,76(3) :187 - 194.
3Kang H ,Kim TJ, Lee YY,et al . Topotecan combined with carbopl-atin in recurrent epithelial ovarian cancer:results of a single-institu-tional phase H study [ J ]. Gynecol Oncol,2009,114 ( 2 ) : 210 -214.
4Muntz HG,Malpass TW,McGonigle KF, et al. Phase II study of intraperiton-eal to potecan as consol idation chemoth erapy in ovarianand primary periton-eal carcinoma[ J]. Cancer,2008,113(3) :490 -496.
5Ma Y, Qian Y,Lv W. The correlation between plasma fibrinogen 1-evels and the clinical features of patients with ovarian carcinoma[J]. J Int Med Res,2007,35(5) :678 -684.
